Topics for Discussion

• Incidence and clinical implications of genetic abnormalities in CLL (eg, 17p deletions, TP53 and IGHV gene mutations)
• Current role of observation for asymptomatic patients with newly diagnosed CLL
• Implications of recent data sets comparing ibrutinib (with or without rituximab) to standard chemoimmunotherapy for younger and older patients with treatment-naïve CLL
• FDA approval of venetoclax/obinutuzumab and patient selection for front-line treatment with this regimen
• Published and emerging efficacy and safety experience with acalabrutinib for treatment-naïve and progressive CLL; comparative tolerability profiles of ibrutinib and acalabrutinib
• Practical administration of venetoclax in the management of progressive CLL; risk of and preemptive measures to prevent tumor lysis syndrome
• Appropriate integration of PI3 kinase inhibitors into current treatment algorithms

A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of chronic lymphocytic leukemia (CLL).

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

• Apply available clinical information and research data to the therapeutic and supportive care of patients with CLL.
• Appreciate the importance of clinical presentation, biomarker profile, coexisting medical conditions and psychosocial status in the selection of systemic therapy for newly diagnosed CLL.
• Discuss available Phase III data demonstrating the superior efficacy and safety of Bruton tyrosine kinase inhibition compared to standard chemoimmunotherapy as first-line therapy for patients with CLL, and use this information to discern how this strategy can be optimally integrated into nonresearch treatment.
• Appraise the Phase III data supporting the recent FDA approval of acalabrutinib for newly diagnosed or previously treated CLL, and identify patients for whom treatment with this agent may be appropriate.
• Assess the FDA approval of venetoclax in combination with obinutuzumab as front-line therapy for CLL, and determine how this regimen can be appropriately integrated into current treatment decision-making.
• Analyze how age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory CLL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with recently approved and emerging systemic therapies employed in the management of CLL in order to support quality of life and continuation of therapy.
• Recognize the biologic rationale for, available research evidence with and ongoing clinical trials evaluating chemotherapy-free combinations for newly diagnosed and progressive CLL, and identify patients who may be suitable candidates for these approaches as part of ongoing research studies.
• Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with CLL to optimize clinical and quality-of-life outcomes.

Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for CNE (NCPD) credit to utilize this program for ONCC certification or renewal. http://www.ResearchToPractice.com/Meetings/ONS2020/CLL/ILNA

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Klebig has no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Ms Goodrich — Advisory Committee: AstraZeneca Pharmaceuticals LP, Janssen Biotech Inc. Dr Kahl — Advisory Committee: AstraZeneca Pharmaceuticals LP; Consulting Agreements: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, BeiGene, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board: Celgene Corporation. Dr Sharman — Advisory Committee, Consulting Agreements and Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, and Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.